Robert Wessman will discuss “The strategy and competitiveness of Actavis in a fiercely competitive environment.”

Actavis today announced that Robert Wessman, Actavis’ President & CEO, will discuss “The strategy and competitiveness of Actavis in a fiercely competitive environment” at the annual UBS Global Specialty and Generic Pharmaceuticals Conference on Wednesday, 28 May 2008.

This year's event will be held in London.

The conference, held in England for the first time in its twelve year history, features presentations from over 80 top executives of leading specialty and generic pharmaceutical companies from North America, Europe, Africa, Latin America and Asia-Pacific, as well as panel discussions focused on key sector trends and issues.